[HTML][HTML] FOXP3 and CTLA4 overexpression in multiple myeloma bone marrow as a sign of accumulation of CD4+ T regulatory cells

WMT Braga, BR da Silva, AC de Carvalho… - Cancer Immunology …, 2014 - Springer
WMT Braga, BR da Silva, AC de Carvalho, YH Maekawa, AB Bortoluzzo, EG Rizzatti
Cancer Immunology, Immunotherapy, 2014Springer
Introduction Multiple myeloma (MM) development involves a series of genetic abnormalities
and changes in the bone marrow (BM) microenvironment, favoring the growth of the tumor
and failure of local immune control. T regulatory (Treg) cells play an important role in
dampening anti-tumor immune responses while T-helper-17 (Th17) cells seem to be critical
for the eradication of malignant cells. The aim of our study was to characterize the
expression of Treg-and Th17-related genes in total myeloma BM samples to assess their …
Introduction
Multiple myeloma (MM) development involves a series of genetic abnormalities and changes in the bone marrow (BM) microenvironment, favoring the growth of the tumor and failure of local immune control. T regulatory (Treg) cells play an important role in dampening anti-tumor immune responses while T-helper-17 (Th17) cells seem to be critical for the eradication of malignant cells. The aim of our study was to characterize the expression of Treg- and Th17-related genes in total myeloma BM samples to assess their role as biomarkers, prognostic factors, and possible therapeutic targets in this incurable disease.
Methods
Expression of markers for Treg (FOXP3, CTLA4) and Th17 cells (RORγt) was determined by quantitative real-time PCR in BM aspirates of 46 MM patients, four patients with monoclonal gammopathy of undetermined significance, five solitary plasmacytomas, and five healthy BM donors. Gene expression was evaluated regarding an influence on the patients’ overall survival (OS).
Results
FOXP3 and CTLA4 presented a sixfold (p = 0.02) and 30-fold higher expression (p = 0.03), respectively, in MM patients than in controls. RORγt expression was similar in MM patients and controls. Median OS of MM patients was 16.8 (range 4.5–29.1) months, and international staging system was the only independent prognostic factor for patients survival.
Conclusions
Overexpression of FOXP3 and CTLA4 in total BM samples suggests a local accumulation of immunosuppressive Tregs, the MM tumor environment, possibly dampening anti-tumor host immune responses. Therapeutic approaches targeting Treg cells and restoring local anti-tumor immunity may provide new treatment strategies for this incurable malignancy.
Springer